Soleno Therapeutics Inc (SLNO) - Net Assets
Based on the latest financial reports, Soleno Therapeutics Inc (SLNO) has net assets worth $495.80 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($608.39 Million) and total liabilities ($112.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SLNO tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $495.80 Million |
| % of Total Assets | 81.49% |
| Annual Growth Rate | N/A |
| 5-Year Change | 2429.73% |
| 10-Year Change | 13003.03% |
| Growth Volatility | 447.56 |
Soleno Therapeutics Inc - Net Assets Trend (2012–2025)
This chart illustrates how Soleno Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See SLNO cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Soleno Therapeutics Inc (2012–2025)
The table below shows the annual net assets of Soleno Therapeutics Inc from 2012 to 2025. For live valuation and market cap data, see market value of Soleno Therapeutics Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $450.12 Million | +83.64% |
| 2024-12-31 | $245.11 Million | +55.62% |
| 2023-12-31 | $157.51 Million | +1422.10% |
| 2022-12-31 | $10.35 Million | -41.84% |
| 2021-12-31 | $17.79 Million | -60.93% |
| 2020-12-31 | $45.55 Million | +204.72% |
| 2019-12-31 | $14.95 Million | -50.85% |
| 2018-12-31 | $30.41 Million | +14.62% |
| 2017-12-31 | $26.53 Million | +672.44% |
| 2016-12-31 | $3.44 Million | +6.56% |
| 2015-12-31 | $3.22 Million | +131.20% |
| 2014-12-31 | $-10.33 Million | +72.71% |
| 2013-12-31 | $-37.86 Million | -10.73% |
| 2012-12-31 | $-34.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Soleno Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 37797673200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $52.00K | 0.01% |
| Other Comprehensive Income | $415.00K | 0.09% |
| Other Components | $881.02 Million | 195.73% |
| Total Equity | $450.12 Million | 100.00% |
Soleno Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Soleno Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
IHS Holding Ltd
NYSE:IHS
|
$2.76 Billion |
|
Apeloa Pharmaceutical Co Ltd
SHE:000739
|
$2.76 Billion |
|
ChengDu Hi-Tech Development Co Ltd
SHE:000628
|
$2.76 Billion |
|
Northeast Securities Co Ltd
SHE:000686
|
$2.76 Billion |
|
Treasury Wine Estates Ltd
AU:TWE
|
$2.76 Billion |
|
Steadfast Group Limited
F:1S6
|
$2.76 Billion |
|
HMS Networks AB (publ)
ST:HMS
|
$2.76 Billion |
|
Bangkok Expressway and Metro Public Company Limited
BK:BEM
|
$2.75 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Soleno Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 245,113,000 to 450,115,000, a change of 205,002,000 (83.6%).
- Net income of 20,890,000 contributed positively to equity growth.
- Share repurchases of 100,146,000 reduced equity.
- New share issuances of 215,721,000 increased equity.
- Other comprehensive income increased equity by 54,000.
- Other factors increased equity by 68,483,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $20.89 Million | +4.64% |
| Share Repurchases | $100.15 Million | -22.25% |
| Share Issuances | $215.72 Million | +47.93% |
| Other Comprehensive Income | $54.00K | +0.01% |
| Other Changes | $68.48 Million | +15.21% |
| Total Change | $- | 83.64% |
Book Value vs Market Value Analysis
This analysis compares Soleno Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.40x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-1830.50 | $53.01 | x |
| 2013-12-31 | $-2026.90 | $53.01 | x |
| 2014-12-31 | $-610.20 | $53.01 | x |
| 2015-12-31 | $25.65 | $53.01 | x |
| 2016-12-31 | $16.61 | $53.01 | x |
| 2017-12-31 | $44.33 | $53.01 | x |
| 2018-12-31 | $21.75 | $53.01 | x |
| 2019-12-31 | $6.57 | $53.01 | x |
| 2020-12-31 | $10.91 | $53.01 | x |
| 2021-12-31 | $3.35 | $53.01 | x |
| 2022-12-31 | $1.23 | $53.01 | x |
| 2023-12-31 | $9.55 | $53.01 | x |
| 2024-12-31 | $6.10 | $53.01 | x |
| 2025-12-31 | $8.28 | $53.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Soleno Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.97%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.25x
- Recent ROE (4.64%) is above the historical average (-121.84%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.06 Million |
| 2013 | 0.00% | -123.57% | 1.89x | 0.00x | $79.20K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.84 Million |
| 2015 | -493.47% | -4104.85% | 0.05x | 2.54x | $-16.23 Million |
| 2016 | -351.22% | -831.63% | 0.26x | 1.62x | $-12.41 Million |
| 2017 | -59.04% | 0.00% | -39.80x | 1.47x | $-18.32 Million |
| 2018 | -43.85% | 0.00% | 0.00x | 1.42x | $-16.38 Million |
| 2019 | -205.89% | 0.00% | 0.00x | 2.55x | $-32.27 Million |
| 2020 | -54.10% | 0.00% | 0.00x | 1.43x | $-29.19 Million |
| 2021 | -173.72% | 0.00% | 0.00x | 2.00x | $-32.69 Million |
| 2022 | -232.58% | 0.00% | 0.00x | 2.56x | $-25.10 Million |
| 2023 | -24.75% | 0.00% | 0.00x | 1.15x | $-54.74 Million |
| 2024 | -71.74% | 0.00% | 0.00x | 1.35x | $-200.36 Million |
| 2025 | 4.64% | 10.97% | 0.34x | 1.25x | $-24.12 Million |
Industry Comparison
This section compares Soleno Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Soleno Therapeutics Inc (SLNO) | $495.80 Million | 0.00% | 0.23x | $2.76 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more